Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles
- 1 February 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (2), 167-168
- https://doi.org/10.1016/j.annonc.2019.11.007
Abstract
No abstract availableFunding Information
- European Research Council (695376-TAROX)
- University of Sheffield (695376-TAROX)
- Cancerfonden (695376-TAROX)
- Vetenskapsrådet (695376-TAROX)
This publication has 7 references indexed in Scilit:
- Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse modelsAnnals of Oncology, 2020
- HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout MiceCancer Research, 2019
- Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsCancer Discovery, 2018
- Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse modelNature Communications, 2017
- Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumorsAnnals of Oncology, 2017
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaThe New England Journal of Medicine, 2015